Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for diseases with high unmet medical need. Its pipeline is centered on endocrine disorders and neurodegenerative diseases, with avexitide as the lead asset and additional programs including AMX0035, AMX0114, and AMX0318. The company previously commercialized RELYVRIO/ALBRIOZA for ALS in the U.S. and Canada, but that product was voluntarily withdrawn from the market in 2024. Today, Amylyx is primarily a research-and-development organization that is trying to convert its pipeline into future commercial products, while relying heavily on third-party manufacturers and potential partners for development and commercialization.

−100,0 %

14.27

14.27

— Amylyx Pharmaceuticals, Inc.
%
Lead clinical asset: avexitide35% Development of avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism.
Neurodegenerative disease programs30% Pipeline programs including AMX0035 and AMX0114 aimed at neurodegenerative and rare neurologic diseases.
Rare endocrine disease programs20% Programs such as AMX0318 and related work targeting PBH and other rare endocrine conditions.
Legacy commercial product5% RELYVRIO/ALBRIOZA, the former ALS product that was voluntarily withdrawn from the market.
Development and manufacturing operations10% Clinical operations, regulatory support, and outsourced manufacturing oversight needed to advance the pipeline.

Amylyx does not currently have a broad commercial customer base because it is primarily a clinical-stage company...

  • Rare endocrine disease patientsprimary

    Patients with post-bariatric hypoglycemia or congenital hyperinsulinism who would use avexitide or related therapies if approved.

  • Neurodegenerative disease patientsprimary

    Patients with ALS, Wolfram syndrome, PSP, and related conditions targeted by AMX0035 and AMX0114.

  • Specialist physicians and treatment centersprimary

    Neurology and endocrinology specialists who diagnose, prescribe, and monitor rare-disease therapies.

  • Payers and reimbursement decision-makerssecondary

    Insurers and health systems that determine access and coverage for high-cost orphan drugs.

  • Commercial collaboratorssecondary

    Partners that may provide sales, marketing, pharmacovigilance, and distribution capabilities for approved products.

Amylyx is headquartered in the United States and its historical commercial activity was concentrated in the U.S...

  • •Headquartered in the United States
  • •Prior product sales were in the U.S. and Canada
  • •Clinical and regulatory work is centered on U.S. development pathways
  • •Foreign patent coverage supports potential international commercialization
  • •Third-party manufacturing and API sourcing create global supply exposure
  • •Geopolitical events and tariffs can affect peptide API availability and cost

Amylyx’s strategy is to build value from a focused pipeline in rare endocrine and neurodegenerative diseases rather...

01
Advance avexitide through development and regulatory milestonesshort-term

Avexitide is the lead asset and the most advanced opportunity to create future commercial revenue.

02
Broaden and de-risk the pipeline beyond avexitidemedium-term

Multiple programs reduce dependence on a single indication and improve long-term optionality.

03
Build commercialization and partnership capabilitiesmedium-term

The company lacks a durable internal sales and distribution engine after the RELYVRIO withdrawal.

04
Preserve capital and extend runwayshort-term

Clinical-stage development requires sustained funding before any product revenue returns.

Amylyx faces the core risk profile of a clinical-stage biotech: most of its value depends on successful clinical...

critical

Pipeline development and regulatory failure

The company’s value depends on a small number of investigational therapies reaching approval and showing meaningful benefit.

Scope
Avexitide, AMX0035, AMX0114, AMX0318
Materiality
high
high

Loss of commercial revenue after RELYVRIO/ALBRIOZA withdrawal

The company no longer generates product sales from its former ALS franchise, increasing dependence on future approvals and financing.

Scope
U.S. and Canada commercial operations
Materiality
high
high

Manufacturing and supply chain dependence

Amylyx relies on third-party CMOs and single manufacturers for APIs and drug product, which can cause delays, shortages, or cost inflation.

Scope
Peptide API supply, cGMP manufacturing
Materiality
high
high

Capital raising risk

Clinical-stage operations consume cash before product revenue is established, so the company may need dilutive financing or strategic transactions.

Scope
Equity, debt, royalty, collaboration funding
Materiality
high
medium

Market size and reimbursement risk

Rare-disease markets may be smaller than expected and payor acceptance may limit uptake even after approval.

Scope
PBH, congenital HI, Wolfram syndrome, ALS
Materiality
medium
medium

Intellectual property protection

Patent coverage is central to protecting future exclusivity and commercial returns in competitive biotech markets.

Scope
Avexitide, AMX0035, AMX0114, AMX0318
Materiality
medium
Acquired in-process R&D
Can materially increase operating losses in the period of acquisition
Accrued research and development expenses
Affects quarterly R&D expense and liabilities
Inventory and purchase commitment write-downs
Can create large one-time cost of sales or operating expense charges
Stock-based compensation
Raises reported SG&A and R&D expense without immediate cash outflow

ALUMIS INC.

ALMS · Pharmaceutical Preparations

NEUROCRINE BIOSCIENCES INC

NBIX · Biological Products, (No Diagnostic Substances)

Immix Biopharma, Inc.

IMMX · Pharmaceutical Preparations

ANAVEX LIFE SCIENCES CORP.

AVXL · Biological Products, (No Diagnostic Substances)

REVIVA PHARMACEUTICALS HOLDINGS, INC.

RVPH · Pharmaceutical Preparations

Axsome Therapeutics, Inc.

AXSM · Pharmaceutical Preparations

: 11/08/2026